# SK Biopharmaceuticals

Type: Company (326030)

Source: GetYourBrief — https://getyourbrief.com/entity/sk-biopharmaceuticals
Canonical HTML page: https://getyourbrief.com/entity/sk-biopharmaceuticals

## Timeline

- **2026-06-22**: Collaboration Announced at BIO 2026 — Insilico Medicine and SK Biopharmaceuticals announced a research and development collaboration, value up to $2.5 billion, to discover AI‑enabled drug candidates for neuroimmune disorders of the CNS.

## Recent coverage (4 stories, network-wide)

### Insilico's 273% Revenue Surge Turns AI Biotech Profitable
2026-07-09 03:18:37 · Sector: finance · Sentiment: Bullish · Impact: 6/10 · Sources: 2

HKEX-listed Insilico Medicine (3696) projects H1 2026 revenue up 273%–287% to $106.5M, swinging to a net profit of up to $39.5M. The surprise profit alert positions the AI biotech as a high-growth, cash-generating investment.
Full story: https://getfinancebrief.com/story/insilico-profit-alert-h1-2026-finance

### AI‑Powered CNS Drug Discovery Deal Hits $2.5B for Neuroimmune Disorders
2026-06-23 04:57:34 · Sector: health · Sentiment: Very Bullish · Impact: 8/10 · Sources: 2

A breakthrough $2.5B collaboration between AI drug discoverer Insilico Medicine and CNS specialist SK Biopharmaceuticals aims to tackle devastating neuroimmune disorders that have long defied conventional drug development. By combining generative AI with established clinical expertise, the partnership could dramatically shorten timelines and deliver first‑in‑class therapies to patients with conditions like Alzheimer's, multiple sclerosis, and rare neuroinflammatory diseases.
Full story: https://gethealthbrief.com/story/insilico-sk-biopharma-2-5b-ai-drug-discovery-neuroimmune

### Insilico's $2.5B AI CNS Biobucks Deal With SK Bio Sets APAC Record
2026-06-23 04:57:27 · Sector: bio · Sentiment: Very Bullish · Impact: 8/10 · Sources: 2

In the largest Asia‑Pacific licensing deal for Insilico Medicine, the AI‑first biotech secured up to $2.5 billion in milestones plus royalties from South Korea's SK Biopharmaceuticals, a CNS powerhouse, to co‑develop next‑generation neuroimmune therapies. The heavily back‑ended structure reflects industry‑standard risk‑sharing, with Insilico taking $18M up front and SK steering commercialization, underscoring a growing appetite for AI‑discovered assets in big pharma pipelines.
Full story: https://getbiobrief.com/story/insilico-sk-biopharma-2-5b-biobucks-record-apac

### $2.5B Partnership: Generative AI Platform Captures Largest CNS Drug Deal
2026-06-23 04:57:18 · Sector: ai · Sentiment: Very Bullish · Impact: 8/10 · Sources: 2

Insilico Medicine's Pharma.AI generative AI platform landed a record $2.5B collaboration with SK Biopharmaceuticals to design and optimize therapeutics for neuroimmune disorders. The deal, announced at BIO 2026, represents the largest validation of an end‑to‑end AI drug discovery engine in the CNS space, proving that generative modeling can transcend oncology and infuse new life into neurology pipelines.
Full story: https://getaibrief.com/story/generative-ai-drug-discovery-pharma-ai-platform-2-5b-skb

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.